Search

Displaying results 671 - 680 of 7537 in total
  1. Drug

    Yellow fever vaccine

    go.drugbank.com/drugs/DB10805
    ApprovedInvestigational

    It is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infection [FDA Label, A32118 … Yellow fever vaccine prevents against Yellow Fever, a viral hemorrhagic disease caused by the transmission of a _flavivirus_ through the bite of an infected mosquito.

  2. Drug

    Bacillus calmette-guerin substrain russian BCG-I live antigen

    go.drugbank.com/drugs/DB16648
    ApprovedInvestigational

    It was developed to alleviate Canada's multi-year shortage of BCG vaccine, and is expected to be available by mid-2021.[L32734] … thought to work by stimulating a local immune and inflammatory response in the bladder.

  3. Drug

    Somapacitan

    go.drugbank.com/drugs/DB15093
    ApprovedInvestigational

    [A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. … [A219146] Somapacitan was granted FDA approval on 28 August 2020.[L15666]

  4. Drug

    Sulfamethoxazole

    go.drugbank.com/drugs/DB01015
    ApprovedInvestigational

    in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. … [L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps

    Synonyms: 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamideMixtures: COMAZOLE N TABLET, Nu-cotrimox Tab 400/80mg
  5. Drug

    Almasilate

    go.drugbank.com/drugs/DB13595
    Approved

    It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer. … However its therapeutic efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and binding bile salts than other conventional antacids [A27138].

  6. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    [L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … [A254571,L44146] On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants.

  7. Drug

    Rosuvastatin

    go.drugbank.com/drugs/DB01098
    ApprovedInvestigational

    elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. … [A181523] This last point results in less risk of drug-drug interactions compared to [atorvastatin], [lovastatin], and [simvastatin], which are all extensively metabolized by Cytochrome P450 (CYP) 3A4,

    Products: Nb-rosuvastatin, RO-ZUTINAR ® 10 MG
  8. Drug

    Xylose

    go.drugbank.com/drugs/DB09419
    ApprovedWithdrawn

    Nevertheless, xylose by itself may not necessarily serve many purposes immediately - but its metabolism results in a variety of substrates that can serve important nutritional and biological purposes. … Xylose has also been used as a diagnostic agent to observe malabsorption. Reduction of xylose by catalytic hydrogenation produces the common food additive sweetener substitute xylitol [DB11195].

  9. Drug

    Eflornithine

    go.drugbank.com/drugs/DB06243
    ApprovedInvestigationalWithdrawn

    [A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric … [A262839] In 1960 and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA for the treatment of African trypanosomiasis and hirsutism, respectively, but has since been discontinued

  10. Indication

    Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

    go.drugbank.com/conditions/DBCOND0080506
    Drugs: Polatuzumab vedotin
    Synonyms: Malignant lymphoma, large B-cell, diffuse, no ICD-O subtype, Malignant lymphoma, large B-cell, diffuse, no International Classification of Diseases for Oncology subtype